Home/Connect Biopharma/Dr. Stephen Bryce
DS

Dr. Stephen Bryce

Former Chief Development Officer

Connect Biopharma

Connect Biopharma Pipeline

DrugIndicationPhase
Rademikibart (CBP-201)Moderate-to-Severe Atopic DermatitisPhase 3
CBP-307Moderate-to-Severe Ulcerative ColitisPhase 2
CBP-174Pruritus in Atopic DermatitisPhase 2